- Global Pharma News & Resources

Press Releases - 2022-03-31

Date Title Company
31-Mar-2022 Iktos Announces a Collaboration With Ono in Artificial Intelligence for New Drug Design Iktos
31-Mar-2022 Novartis UK response to NICE Appraisal Consultation Document (ACD) for Piqray (alpelisib) for advanced breast cancer patients Novartis
31-Mar-2022 Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement (news with additional features) Vivoryon Therapeutics N.V.
31-Mar-2022 Original-Research: M1 Kliniken AG (von First Berlin Equity Research GmbH) M1 Kliniken AG
31-Mar-2022 Avance Clinical Announces New Office Opening in Melbourne Avance Clinical
31-Mar-2022 Immutep’s efti in combination with MSD’s pembrolizumab shows encouraging antitumor activity in difficult to treat second line metastatic lung cancer patients Immutep Limited
31-Mar-2022 Fitabeo Therapeutics shortlisted for National StartUp Award Fitabeo Therapeutics
31-Mar-2022 Solvay Brussels School of Economics and Management joins forces with the Belgian life sciences ecosystem to train the next generation of Biotech and MedTech leaders Solvay Brussels School of Economics and Management
31-Mar-2022 TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer TILT Biotherapeutics
31-Mar-2022 V-Bio Ventures raises EUR 110 million for its second fund and expands team V-Bio Ventures
31-Mar-2022 Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines Sanofi
31-Mar-2022 Pharma Business Development: In-person Format Clearly Beats Video Conferencing RauCon GmbH & Co. KG
31-Mar-2022 Maruho Deutschland GmbH: Statement of Maruho Deutschland GmbH on the proposed capital measures in the context of the Extraordinary General Meeting on 7 April 2022 Maruho Deutschland GmbH
31-Mar-2022 Körber wins two awards at the Asia-Pacific Bioprocessing Excellence Awards for its state-of-the-art solutions for life sciences industry Körber
31-Mar-2022 Turnaround in FY/2021: Significant sales growth (+30%) and substantially improved EBIDTA (+84%) - clear trend towards black zero aap Implantate AG
31-Mar-2022 Relief Reports Full-Year 2021 Results and Provides Corporate Update Relief Therapeutics Holding SA
31-Mar-2022 AEVIS VICTORIA SA achieved very strong results on its investments in 2021 with a holding income of CHF 216.4 million and a net profit of CHF 197.6 million AEVIS VICTORIA SA